Compare GSK plc (GSK) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Orion Office REIT Inc — how do they compare? GSK plc trades at $52.7 (market cap $101.34B), while Orion Office REIT Inc trades at $2.69 (market cap $151.17M). The key difference: GSK plc is far larger — about 670.4× Orion Office REIT Inc's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | ONL | |
|---|---|---|
Market Cap | $101.34B | $151.17M |
Sector | Health | Real Estate |
52-Week High | $61.18 | $3.04 |
52-Week Low | $36.20 | $1.93 |
Enterprise Value | $121.95B | $634.82M |
Dividend Yield | 3.49% | 3.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
ONL trades at $2.695, up 1.32% with a bearish technical signal. The REIT shows declining revenue from $208M in 2022 to $148M in 2025 and persistent net losses, with a -98.36% net margin. However, positive cash flow from operations and a strategic review with Wells Fargo and JPMorgan provide some optimism. Analyst sentiment is split evenly between Buy and Hold recommendations.
The outlook is challenged by fundamental weakness but supported by balance sheet management efforts. Investment opportunity lies in the potential outcome of the strategic review and portfolio repositioning. Key risks include continued revenue erosion, high debt levels, and negative funds from distribution amid significant capital expenditures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
